Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.22 HKD | +0.38% | +3.57% | -21.39% |
05-02 | Alphamab Oncology's 2023 Loss Narrows as Revenue Rises | MT |
04-10 | Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.39% | 625M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+45.09% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- 9966 Stock
- News Alphamab Oncology
- UBS Adjusts Alphamab Oncology's Price Target to HK$12.94 From HK$13.22, Keeps at Buy